NASDAQ:CTOR Citius Oncology (CTOR) Stock Price, News & Analysis $0.92 +0.04 (+3.93%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.91 -0.02 (-1.62%) As of 05/2/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Citius Oncology Stock (NASDAQ:CTOR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Citius Oncology alerts:Sign Up Key Stats Today's Range$0.91▼$0.9850-Day Range$0.57▼$1.1952-Week Range$0.55▼$4.42Volume102,364 shsAverage Volume1.17 million shsMarket Capitalization$66.19 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewCitius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Read More… Receive CTOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CTOR Stock News HeadlinesWall Street Set to Open Lower Monday as Investors Gird for More Tariffs, Await Key Manufacturing DataApril 1, 2025 | msn.comInvestors Brace for 'Liberation Day' as US Futures Trend Sharply Lower in Monday's PremarketMarch 31, 2025 | msn.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 3, 2025 | Porter & Company (Ad)CTOR Citius Oncology, Inc.February 20, 2025 | seekingalpha.comCitius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdateFebruary 14, 2025 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdateFebruary 14, 2025 | prnewswire.comCitius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid ServicesFebruary 6, 2025 | prnewswire.comCitius Oncology’s Strategic Positioning and Lymphir’s Market Launch Drive Buy RatingJanuary 10, 2025 | markets.businessinsider.comSee More Headlines CTOR Stock Analysis - Frequently Asked Questions How have CTOR shares performed this year? Citius Oncology's stock was trading at $1.15 at the beginning of the year. Since then, CTOR shares have decreased by 19.6% and is now trading at $0.9250. View the best growth stocks for 2025 here. How were Citius Oncology's earnings last quarter? Citius Oncology, Inc. (NASDAQ:CTOR) released its quarterly earnings data on Friday, February, 14th. The company reported ($0.09) EPS for the quarter. How do I buy shares of Citius Oncology? Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Citius Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC). Company Calendar Last Earnings2/14/2025Today5/03/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTOR Previous SymbolNASDAQ:CTOR CIK1851484 Webwww.citiusonc.com Phone347-627-0058FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+224.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,150,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.67% Return on Assets-9.74% Debt Debt-to-Equity Ratio0.08 Current Ratio0.34 Quick Ratio0.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.22) per share Price / Book-4.20Miscellaneous Outstanding Shares71,552,000Free Float55,167,000Market Cap$66.19 million OptionableN/A Beta-0.19 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:CTOR) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.